Objective: We used brain radiotherapy as a surrogate for the presence of brain metastases in patients with non-small cell lung cancer (NSCLC) to determine the prevalence of brain metastases using the Surveillance Epidemiology and End Results database.
L ung cancer is the leading cause of cancer-related death in the United States, accounting for more deaths than colon cancer, breast cancer, and prostate cancer combined. 1 Brain metastases are a significant problem in patients with lung cancer, accounting for approximately half of all solid tumor metastases to the brain. 2, 3 It has been estimated that 16% to 22% of patients with lung cancer develop brain metastases from lung cancer. [4] [5] [6] The apparent incidence of brain metastases has been increasing due to widespread availability of imaging modalities such as magnetic resonance imaging, with detection of subclinical disease. In addition, due to recent advances in systemic therapy for non-small cell lung cancer (NSCLC), patients tend to live longer, with more time to develop metastasis in sanctuary sites such as the brain. 2, 7 Although prophylactic cranial irradiation has been shown to improve survival in patients with small cell lung cancer, this benefit has not been observed in patients with NSCLC. 8 Even with treatment, the prognosis for these patients remains poor, with a median survival of 7 months, but patients with systemic disease control, brain only metastasis, good performance status, and younger age have better outcomes. [9] [10] [11] Although several groups have performed smaller population-based studies to determine the incidence of brain metastasis, these estimates vary by trial design and are limited by small sample size and nonuniform patient populations. [4] [5] [6] To the best of our knowledge, the frequency of brain metastasis in patients with NSCLC at initial presentation has not been described. In addition, although certain clinical factors such as age, histology, sex, and molecular subtype have been linked to frequency of developing brain metastasis, the joint effect of these factors taken together in predicting brain metastasis has not been examined. 6, 12 We sought to systematically address these questions using the population-based Surveillance, Epidemiology, and End Results (SEER) database, which provides information regarding the initial treatment, including indication for brain radiotherapy. 
METHODS
We searched the SEER-17 registry data for patients with NSCLC diagnosed over a 10-year period between January 1, 1988 and December 31, 1997. The database does not record sites of metastasis or brain metastasis specifically, but does record the use of radiation therapy at the time of initial diagnosis. In this study, we used "brain radiation therapy indicated" as a surrogate for early brain metastasis. We subdivided our patient cohort according to brain radiotherapy data into "none" or "radiation therapy indicated." The latter group included patients in whom brain radiotherapy was given, those in whom brain radiotherapy was indicated but the patient either refused or it is unknown if the patient actually received brain radiotherapy. We identified a total of 142,023 patients, 131,456 of whom had a known brain irradiation status. Patients without information regarding the indication for brain radiotherapy were listed as "unknown" (n = 10,567), and were excluded from our patient cohort.
Demographic and clinical variables included age at diagnosis, sex, race, histology, tumor size, tumor grade, lymph node status (N), and American Joint Committee on Cancer (AJCC) stage. Age at diagnosis was analyzed as a continuous variable. Tumor size was subdivided into r3, 3.1 to 5, 5.1 to 7, and >7 cm to match the AJCC 7th edition staging for T1, T2a, T2b, and T3, respectively. The histology was coded according to the International Classification of Diseases for Oncology (ICD-O-3) into adenocarcinoma (8140-8147, 8255, 8260, 8310, 8323, 8480, 8481, 8490, 8550, 8572), squamous cell carcinoma (8050-8052, 8070-8078), large-cell carcinoma (8012-8014), and other histologies including undifferentiated tumors (8020-8022) and carcinomas not otherwise specified (8010). We excluded bronchioloalveolar carcinoma (8250-8254) because its natural history and clinical course differs from other subtypes of NSCLC.
Statistical Analysis
Single and multivariable variable logistic regression analysis explored the association of age at diagnosis, sex, race, tumor histology, tumor size, tumor grade, N stage, and AJCC stage in the presence of radiotherapy of the brain. Variable selection criteria included model fit criteria (deviance and deleted residual diagnostics) and Akaike Information Criteria to assess individual and joint contribution of covariates to the probability of brain radiotherapy. To reduce the risk of overfitting and of identifying small effects or chance interactions as apparently statistically significant, given the large sample size, covariate selection also was based on literature review. Race did not contribute information to the multivariable model, suggesting that the information it provides about brain irradiation is also contained by the other predictors. AJCC stage was excluded as brain irradiation was rare outside stage IV. AJCC stage is also partly redundant with N stage, a predictor of greater clinical interest. There was a small but measurable decline in the rate of brain radiotherapy over the 10 years of the study, so the multivariable model was adjusted for year of diagnosis. All patients have data on age at diagnosis, sex, tumor histology (as a function of sample selection), and year of diagnosis. Missing data occurred in tumor grade (39.7%), tumor size (41.6%), N stage (37.8%), and AJCC stage (23.7%). Imputation of such a large amount of missing data was considered unreliable, and the missing values were included in a separate "unknown" category. There were 41,710 patients (31.7%) with complete data for all covariates. An analysis of these patients indicated that the incidence of brain irradiation was lower than in all 131,456 patients (6.1%, as opposed to 8 .3% in all 131,456 patients). Figure 2 uses a color intensity scale to summarize increases of 5% in the frequency of brain irradiation (0% to 4.9%, 5% to 9.9%, 10% to 14.9%, 15% to 19.9%, 20% to 24.9%, and 25% to 50%, the maximum observed frequency) for patients having each combination of prognostic features. In this illustration age at diagnosis is in 4 categories. Adjusted odds ratios (ORs) were calculated with 95% confidence intervals and a receiver operation curve summarizes the information about the outcome contained in the multivariable model predictors.
RESULTS

Demographics
A total of 142,023 patients were identified, who met the inclusion criteria, of whom we excluded 10,567 patients due to unknown brain radiotherapy status. The remaining 131,456 patients comprised our cohort (Fig. 1 
Use of Brain Radiotherapy
Brain radiation was indicated in 10,567 (8.3%) of the 131,456 patients with NSCLC, which included patients with all disease stages. On the basis of the univariate analysis, predictors of brain radiotherapy included younger age; black race; tumor size of >3 cm; higher grade tumors (grade III or higher); N1, N2, or N3 lymph node involvement; and AJCC stage greater than stage I (Table 1) .
On multivariate analysis, characteristics of patients most likely to receive brain radiotherapy include younger age; nonsquamous histology; tumor size > 3 cm; tumor grade III or IV; and N1, N2, or N3 nodal involvement ( Table 2, Figs. 2, 3) . Taken jointly and adjusted for year of diagnosis, brain irradiation is about 35% less likely with each 10-year increase in age (OR, 0.65), and it is 5% more likely in female patients than in male patients (OR, 1.05). Relative to squamous cell tumors, brain irradiation is 67% more likely in both adenocarcinomas and in large cell than other histologies (OR, 1.67 in both cases). Brain irradiation is 80% to 90% more likely to occur among patients with undifferentiated or poorly differentiated tumors (grades III and IV) than in moderately or well-differentiated tumors (grades I and II) (OR, 1.82 and 1.91, respectively). Brain irradiation is also 22% to 25% more likely in tumors >3.1 to 5 cm or >5 cm than in those <3 cm (OR, 1.22 and 1.25, respectively). N stage N1 raises the odds of brain irradiation by 33% (OR, 1.33), whereas N2 or N3 raises the odds by >2 times (OR, 2.24 and 2.39, respectively). The area under the receiver operating curve analysis was 0.70 (Fig. 4) .
DISCUSSION
In our study, brain radiation was indicated in over 8% of patients with NSCLC within the first 4 months of diagnosis. This proportion is likely an underestimate of the true frequency of brain metastasis at presentation, as staging with brain magnetic resonance imaging was not commonly used in the selected study time frame. The SEER database also captures patients in whom radiation was indicated, but not received, which may include patients with poor performance status, who are usually otherwise excluded from prospective studies following patients for eventual development of brain metastasis. 13 These data does not include information regarding molecular abnormalities in the tumor, including presence of activating mutations of the epidermal growth factor receptor tyrosine kinase domain, and anaplastic lymphoma kinase gene rearrangements, which are now routinely checked at presentation. Such patients would likely be treated with molecularly targeted agents that penetrate the cerebrospinal fluid, and not receive brain radiation upfront for asymptomatic brain metastases. However, the time period of this study predates routine assessment for these molecular abnormalities. 
